Drug intelligence / Profile preview

vancomycin + amoxicillin

Development stage
Unknown
Lead developer
Eli Lilly
Modality
Small Molecules
Administration
Intravenous, Oral
01

Overview

A combination of two antibiotics used to treat bacterial infections. Vancomycin is a glycopeptide antibiotic primarily used to treat severe bacterial infections, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA). It works by inhibiting bacterial cell wall assembly. Amoxicillin is a penicillin-type antibiotic that is often combined with clavulanic acid to treat various bacterial infections. When used together, vancomycin and β-lactam antibiotics (like amoxicillin) have shown synergistic effects against methicillin-resistant staphylococci. This combination can be more effective than either antibiotic alone, particularly against strains with reduced susceptibility to glycopeptides. In clinical practice, this combination might be used for serious infections such as endocarditis caused by resistant staphylococcal strains. Research in rabbit models of experimental endocarditis has shown that the combination of vancomycin with β-lactams (specifically nafcillin in the study) resulted in significant reductions in bacterial counts compared to either agent alone. The dosing of these antibiotics would typically follow standard guidelines for each individual drug. This combination represents an important therapeutic strategy for managing difficult-to-treat resistant bacterial infections, particularly when standard monotherapy approaches may be insufficient.

02

Targets

PBP (Penicillin-binding protein family)D-Ala-D-Ala (D-Ala-D-Ala terminus)

Beyond the preview

Go deeper on vancomycin + amoxicillin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on vancomycin + amoxicillin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call